Page last updated: 2024-11-12

bde 183

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2,2',3,4,4',5',6-heptabromodiphenyl ether: a polybrominated diphenyl ether compound [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID15509899
CHEMBL ID219178
CHEBI ID81537
SCHEMBL ID14938742
MeSH IDM0472858

Synonyms (22)

Synonym
207122-16-5
2,2',3,4,4',5',6-heptabde
2,2',3,4,4',5',6-heptabromodiphenyl ether
pbde 183
bde 183
bde-183
benzene, 1,2,3,5-tetrabromo-4-(2,4,5-tribromophenoxy)-
2,2',3,4,4',5',6-heptabromodiphenylether
chebi:81537 ,
CHEMBL219178
1,2,3,5-tetrabromo-4-(2,4,5-tribromophenoxy)-benzene
C18140
unii-6m82n9dxai
6m82n9dxai ,
DTXSID8052693
SCHEMBL14938742
ILPSCQCLBHQUEM-UHFFFAOYSA-N
1,2,3,5-tetrabromo-4-(2,4,5-tribromophenoxy)benzene
J-013540
Q27155453
pbde no. 183
pbde 183 50 microg/ml in nonane

Research Excerpts

Toxicity

ExcerptReferenceRelevance
"The toxic effects of two brominated diphenyl ethers (BDE), BDE-47, and BDE-183, on a benthic oligochaete tubificid, Monopylephorus limosus were studied under laboratory conditions."( Toxic effects of two brominated flame retardants BDE-47 and BDE-183 on the survival and protein expression of the tubificid Monopylephorus limosus.
Chiu, KH; Huang, HW; Lin, CR; Liu, LL; Shiea, J, 2012
)
0.38

Bioavailability

ExcerptReferenceRelevance
" The main reason for their concentration decrease or absence in biota may be due to low bioavailability potential or due to biotransformation processes."( Congener distribution of polybrominated diphenyl ethers in feral carp (Cyprinus carpio) from the Llobregat River, Spain.
Barceló, D; Eljarrat, E; Labandeira, A, 2007
)
0.34
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
aromatic etherAny ether in which the oxygen is attached to at least one aryl substituent.
organobromine compoundA compound containing at least one carbon-bromine bond.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID274424Displacement of androgen fluormone from androgen receptor at 100 uM2006Journal of medicinal chemistry, Dec-14, Volume: 49, Issue:25
Identification of the brominated flame retardant 1,2-dibromo-4-(1,2-dibromoethyl)cyclohexane as an androgen agonist.
AID274429Activity against human androgen receptor expressed in HepG2 cells assessed as renilla reporter gene activation in presence of 1 nM DHT at 1 uM after 40 hrs2006Journal of medicinal chemistry, Dec-14, Volume: 49, Issue:25
Identification of the brominated flame retardant 1,2-dibromo-4-(1,2-dibromoethyl)cyclohexane as an androgen agonist.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (28)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's8 (28.57)29.6817
2010's19 (67.86)24.3611
2020's1 (3.57)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 19.09

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index19.09 (24.57)
Research Supply Index3.37 (2.92)
Research Growth Index4.82 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (19.09)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (3.57%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other27 (96.43%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]